A pproximately 50% of cutaneous malignant melanomas (CMMs) harbor an activating BRAF (OMIM 164757) mutation. 1 Approximately 80% of all BRAF mutations detected in CMMs are the result of a substitution of a single amino acid at codon 600, glutamic acid for valine (BRAF V600E ), in exon 15. 1 Another less commonly reported BRAF mutation is the substitution of valine for lysine (BRAF V600K ). 2 These mutations constitutively activate the BRAF protein, which induces activation of the mitogen-activated protein kinase pathway, thereby promoting tumor cell proliferation and preventing apoptosis. BRAF V600E mutations are associated with superficial spreading melanomas (SSMs), younger age at diagnosis, and truncal tumor location. 3, 4 Acral lentiginous melanoma (ALM) is a rare subtype of CMM, accounting for less than 5% of all diagnosed CMMs. Compared with other subtypes of CMM, ALM harbors significantly fewer BRAF mutations, which are present in approximately 15% of ALMs. 5 With the development of specific small-molecule BRAF inhibitors, the therapeutic responses in patients with BRAF V600E metastatic CMM have been significantly improved. Targeted therapy with BRAF inhibitors (vemurafenib and dabrafenib) have improved progression-free and median overall survival compared with treatment with conventional cytotoxic chemotherapy. 6, 7 Moreover, MEK inhibitors as single agents or in combination with BRAF inhibitors have efficacy as single agents in CMMs with BRAF V600E mutations and, in combination with BRAF inhibitors, can delay resistance and further prolong survival compared with BRAF inhibitors as monotherapy. 8, 9 Thus, the rapid development of targeted therapies with BRAF/extracellular signal-regulated kinase inhibitors mandates determination of BRAF mutation status in patients with advanced CMM. A variety of DNA-based tests to determine the BRAF genotype are available. 10 Immunohistochemical analysis using a monoclonal BRAF V600E mutationspecific antibody has been evaluated, suggesting high sensitivity and specificity. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The advantages of immunohistochemical analysis include that it requires less tumor tissue, is less expensive, and is more rapid to perform compared with standard molecular techniques. Immunohistochemical analysis also allows visualization of a mutated protein in single cells or a very small number of cells, which would be difficult to detect by standard DNA analysis tests; moreover, immunohistochemical analysis is established as a routine in pathology departments. Previous studies 11, 14, [17] [18] [19] [20] analyzing primary CMMs and metastases have focused mainly on the major subtypes of CMM (SSM and nodular melanoma [NM]), and a low proportion of differing BRAF V600E protein expression in primary tumors and metastases has been reported. Our aim was to characterize the patterns of expression of BRAF V600E mutated protein in primary CMMs and the corresponding metastases, using the BRAF V600E mutation-specific antibody VE1 in a large sample of CMMs of different subtypes. We also analyzed the sensitivity and specificity of VE1 immunohistochemical analysis to determine the use of the method in clinical practice.
Methods

Tumor Samples
The study was approved by the Regional Ethical Review Board at Karolinska Institutet. Informed consent was not required. Tumor tissues from primary CMMs and stage III to IV metastatic disease were analyzed. All tissue samples were formalin-fixed, paraffin-embedded (FFPE) surgical excision biopsy specimens from patients treated and followed up at the Department of Oncology, Karolinska University Hospital from September 2012 to September 2013. Individual information on clinical characteristics, tumor characteristics, surgical treatment, and follow-up was collected from the Stockholm-Gotland Regional Melanoma Register in Sweden.
Mutation Analysis
This cohort of tumor samples has previously been tested for BRAF (exon 15) and NRAS (OMIM 164790) (exon 2) mutations.
5,21
The BRAF and NRAS mutation status in the ALM subtypes has been determined by using direct DNA sequencing, 5 whereas in the remaining histologic subtypes single-strand conformational polymorphism analysis, followed by sequencing, has been used. 21 The tumor samples were microdissected (when the samples contained few tumor cells) or macrodissected (when tumor cells were abundant in the samples). The microdissected and macrodissected samples contained at least 70% tumor cells. Reanalysis of patients with discordant findings between the mutation analyses and the VE1 immunohistochemical analyses was performed by pyrosequencing using PyroMark Q24 software (Qiagen), on the same FFPE blocks as for the initial analysis, to confirm or revise the results of the initial mutation analyses. In these patients, tumor cells were microdissected from 5-μm-thin paraffin tissue sections. DNA was extracted using a QIAamp DNA FFPE Tissue Kit (Qiagen). The primers used for pyrosequencing were the BRAF forward primer AAGACCTCACAGTAAAAATAGG and the BRAF reverse primer TAGCCTCAATTCTTACCATCC, which were biotinylated at the 5′ end. Standard polymerase chain reaction amplification was performed using the 1× AmpliTaq Gold 360 Master Mix (Life Technologies Corporation) and 50 ng of genomic DNA in 25-μL reactions. The preparation of single-stranded DNA from the biotinylated amplicons (reverse strands) was performed using streptavidincoated sepharose beads and processed on a PyroMark Q24 Vacuum workstation according to the manufacturer's protocol. Sequencing reactions were performed using 0.3-μmol/L forward sequencing primer TAGGTGATTTTGGTCTAGCT using the dispensation order CAGTACGATCT. The pyrograms were interpreted visually using PyroMark Q24 software (Qiagen).
Using single-strand conformational polymorphism, Omholt et al 22 found that 10% of mutated cells are enough for detection of mutations, with the most critical parameter being the size of the DNA fragment being evaluated. Sanger sequencing detects mutations when at least 20% of the alleles in a DNA
Immunohistochemical Analysis
Immunohistochemical analysis for BRAF V600E was performed on FFPE sections 4-μm thick using the monoclonal mouse BRAF V600E -specific antibody VE1 (provided by Andreas von Deimling, MD, PhD, University of Heidelberg). Staining was performed on a Ventana BenchMark XT immunostainer (Ventana Medical Systems) according to a previously described protocol. 11 However, because the staining performed initially was generally very weak or negative in most tumors, we increased the VE1 antibody incubation from 32 minutes, as described by Capper et al, 11 to 60 minutes. The negative controls were incubated with trisbuffered saline instead of primary antibody. All sections were also incubated with a monoclonal wild-type (wt) BRAF mouse antibody Raf-B (F-7) (Santa Cruz Biotechnology Inc) using the same machine and protocol. The Raf-B (F-7) antibody was diluted 1:500 after evaluation of several different concentrations.
The evaluation of the VE1 staining status was performed independently by 3 observers (H.E., A.Z., and I.V.) who were masked to all genetic, histopathologic, and clinical data. When clear cytoplasmic staining with VE1 antibody was observed, the result was interpreted as positive and was scored as weak, moderate, or strong ( Figure 1A-C) . Faint or weak staining of single interspersed cells, staining of immune cells only, and faint diffuse staining was scored as negative ( Figure 1D ). The staining was scored as unspecific in cases of weak cytoplasmic staining that differed in color compared with positive cases 
Results
The clinical and tumor characteristics of primary CMMs and metastases are given in Table 1 and Table 3) .
Among the metastases, the corresponding numbers were as follows: BRAF V600E (n = 33), BRAF V600K (n = 2), BRAF muta- Table 4) .
Expression of VE1 Antibody in Primary and Metastatic Melanomas
Overall, 63 of the 135 tumors (46.7%) stained positive with the VE1 antibody (Table 3 and Table 4 ). All tumors with BRAF
V600K
and BRAF mutations outside codon 600 had negative stain results. Most of the BRAF V600E mutated primary tumors and metastases that were VE1 positive stained moderate to strong (75% and 78%, respectively). However, 21 (14 primary tumors and 7 metastases) of the VE1-positive tumors were weakly stained despite adjustments of the incubation time. In 10 of the 200 tumors (5.0%), mainly in primary CMMs, an intratumoral heterogeneous expression of VE1 was detected (Figure 2A and B). The VE1 staining was clearly present in tumor cells from primary CMMs in the radial growth phase (RGP) and vertical growth phase (VGP) when present ( Figure 2C ). In tumors in which results of immunohistochemical and mutation analysis had discordant or unspecific staining (n = 12) ( Figure 1E and F) , resequencing was performed when enough tumor material was available (9 of 12 tumors). In 3 tumors (2 primary tumors and 1 metastasis), a previously unidentified BRAF V600E mutation was found, corresponding to positive VE1
staining. The results reported in Table 3 and Table 4 
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staining (Table 3 and Table 4 ). The discordant CMMs were reevaluated by a dermatopathologist (I.V.). Before macrodissection or microdissection, all false-positive primary tumors (n = 5) had a moderate to high fraction of CMM cells (range, 70%-90%), with few inflammatory cells and a low fraction of stromal cells. The melanin content was low. The tumor thickness ranged from 1.2 to 8.2 mm. The false-negative primary CMMs (n = 2) were T1 tumors (tumor thickness range, 0.6-0.8 mm) with a low fraction of tumor cells (approximately 40%) and a higher fraction of inflammatory and stromal cells compared with the false-positive tumors. Preexisting nevi were found in neither the false-positive nor the false-negative samples.
In the primary and metastatic CMMs together, the estimated sensitivity of the VE1 antibody, related to DNAsequencing results, was 96.7% (n = 88 of 91) and the specificity was 94.5% (n = 103 of 109) (eTable 1 in the Supplement). The positive and negative predictive values were 93.6% (n = 88 of 94) and 97.2% (n = 103 of 106), respectively (eTable 1 in the Supplement). A high sensitivity was registered for the primary ( 
VE1 Expression in Matched Primary and Metastatic CMMs
Overall, the staining with VE1 antibody corresponded to the mutational status among the matched tumors (63 primary CMMs and 73 matched metastases). The histologic type of matched primary CMMs included SSM (n = 29), NM (n = 19), ALM (n = 13), and unclassified (n = 2). The intensity of the VE1 staining differed between the primary tumors and the metastases in 94 of the 200 tumors (47.0%), with weaker staining found in the corresponding metastasis. Except for 2 tumors, the VE1 staining intensity differed among the multiple metastases from the same patient. In 4 CMMs (3.0%), the BRAF mutation status differed between the primary tumors and the matched metastases (eTable 2 in the Supplement). In these cases, the VE1 staining status corresponded to the BRAF mutation status of each tumor (eTable 2 in the Supplement).
Discussion
Analyses of the expression of BRAF V600E protein by the mutation-specific monoclonal antibody VE1 using immunohistochemical analysis in primary and metastatic CMMs are highly sensitive and less time consuming for detection of BRAF
V600E
mutations compared with DNA-based methods. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The method has also been reported to have a good interobserver reproducibility. 18, 24 In this report, we included a large number of tumors, thus enabling a comparison of the BRAF V600E protein expression using the VE1 antibody in different subtypes of CMM and between primary tumors and their corresponding metastases. Altogether, our results are in concordance with published data on the sensitivity and, among metastases, the specificity of the VE1 antibody. 12, 13, 17, 20 Of interest, among the primary CMMs, we found a somewhat lower specificity for the antibody than previously reported. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In a recent study by Es- This finding indicates the presence of intertumoral and intratumoral heterogeneity in BRAF mutation status in CMM, which is supported by our findings of a change of mutational status in 4 corresponding tumors.
The major strengths of this study are the large number of CMMs analyzed, including 124 primary tumors, and the inclusion of matched primary tumors and metastases with detailed, prospectively collected information on clinicohistopathologic data. The main limitation is that the present study included CMM tumor samples prepared at several different pathology laboratories, which may have contributed to variability of results. The observers experienced difficulties in differentiating unspecific background staining from very weak VE1 staining among BRAF V600E and BRAF wt primary CMMs. Long et al 12 also found that immunohistochemical analysis with the VE1 antibody was more easily assessed in metastases, although both V600E-mutated primary and metastatic CMMs stained positively. BRAF V600E -specific immunohistochemical analysis has previously been reported to be highly sensitive using FFPE CMM tissue. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] We analyzed a retrospective cohort of FFPE tumors with matched metastases and found a slightly lower specificity for the VE1 immunohistochemical analysis in primary tumors compared with metastases and in particular when tumors lacked strong staining than previously reported, which is important in clinical practice.
Conclusions
It is preferable to analyze metastatic rather than primary CMMs with the VE1 antibody. Tumors with positive results, including strong VE1 staining, should be expedited for confirmatory BRAF mutation testing. If this test result is negative, consideration of a false-negative result of the mutation analysis should be entertained. However, this conclusion should be modified pending additional studies and validation of VE1 immunohistochemical analysis in clinical routine.
